Quick Answer
PLUS THERAPEUTICS, INC. reported Operating Income Loss of -$15.30 million for the year ending 2025.
- PLUS THERAPEUTICS, INC. showed a decrease of -4.1% in Operating Income Loss from 2024 to 2025.
- This data is from PLUS THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), PLUS THERAPEUTICS, INC.'s Operating Income Loss has grown by 29.0%.
- Historical annual values: Fiscal year 2025: -$15.30 million | Fiscal year 2024: -$14.70 million | Fiscal year 2023: -$13.32 million | Fiscal year 2022: -$19.71 million | Fiscal year 2021: -$12.49 million | Fiscal year 2020: -$9.58 million | Fiscal year 2019: -$3.66 million | Fiscal year 2018: -$8.76 million | Fiscal year 2017: -$20.68 million | Fiscal year 2016: -$19.71 million | Fiscal year 2015: -$15.29 million | Fiscal year 2014: -$32.44 million | Fiscal year 2013: -$30.68 million | Fiscal year 2012: -$28.42 million | Fiscal year 2011: -$29.41 million | Fiscal year 2010: -$25.32 million | Fiscal year 2009: -$21.55 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: